Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
Yago Nieto
No relevant relationships to disclose
Nizar M. Tannir
No relevant relationships to disclose
Shi-Ming Tu
No relevant relationships to disclose
Roy B. Jones
No relevant relationships to disclose
Amado J. Zurita
No relevant relationships to disclose
Ana Aparicio
No relevant relationships to disclose
Roland Bassett
No relevant relationships to disclose
Kim Allyson Margolin
No relevant relationships to disclose
Leona Holmberg
No relevant relationships to disclose
Richard E. Champlin
No relevant relationships to disclose
Lance C. Pagliaro
No relevant relationships to disclose